Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cedars-Sinai Medical Center
The overarching goal of this pilot study is to evaluate the usefulness of a novel Magnetic Resonance Imaging (MRI) approach, which measure properties of tumor microenvironment (i.e. vascularity, fibrosis), to predict PDAC response to neoadjuvant therapy (NAT).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pancreatic cancer patients (with resectable or borderline resectable or locally advanced tumors) who will undergo neoadjuvant chemotherapy
Patients able to undergo at least two sets of MRI sessions
You may not be if
Patients who have previously been treated for PDAC
Patients unable to undergo MRI exam w/contrast
Patients with metastatic pancreatic cancer visualized on index diagnostic imaging
Patients with certain metallic implants
Patients experiencing claustrophobia
Persons with allergy to animal dander or animal-instigated asthma
